MA26531A1 - PHARMACEUTICAL COMPOSITION - Google Patents

PHARMACEUTICAL COMPOSITION

Info

Publication number
MA26531A1
MA26531A1 MA25211A MA25211A MA26531A1 MA 26531 A1 MA26531 A1 MA 26531A1 MA 25211 A MA25211 A MA 25211A MA 25211 A MA25211 A MA 25211A MA 26531 A1 MA26531 A1 MA 26531A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
MA25211A
Other languages
French (fr)
Inventor
Alan Frank Parr
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26531A1 publication Critical patent/MA26531A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA25211A 1997-08-19 1998-08-12 PHARMACEUTICAL COMPOSITION MA26531A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9717428.8A GB9717428D0 (en) 1997-08-19 1997-08-19 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MA26531A1 true MA26531A1 (en) 2004-12-20

Family

ID=10817619

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25211A MA26531A1 (en) 1997-08-19 1998-08-12 PHARMACEUTICAL COMPOSITION

Country Status (15)

Country Link
EP (1) EP1007010A2 (en)
JP (1) JP2002511101A (en)
KR (1) KR20010014080A (en)
CN (1) CN1263461A (en)
AR (1) AR016629A1 (en)
AU (1) AU9343098A (en)
BR (1) BR9810458A (en)
CA (1) CA2295016A1 (en)
CO (1) CO4960657A1 (en)
GB (1) GB9717428D0 (en)
MA (1) MA26531A1 (en)
PE (1) PE105699A1 (en)
TR (1) TR199903209T2 (en)
WO (1) WO1999008666A2 (en)
ZA (1) ZA987392B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS6633A (en) * 2002-11-22 2004-05-23 Omega Farma Ehf. Compositions of finasteride tablets
US7635675B2 (en) 2003-08-13 2009-12-22 Biocon Limited Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
WO2005066195A1 (en) * 2004-01-02 2005-07-21 Pharmacon Forschung Und Beratung Gmbh Method for producing 1,2-unsaturated azasteroids
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
US9011908B2 (en) 2009-04-06 2015-04-21 Banner Life Sciences Llc Progesterone solutions for increased bioavailability
ES2385240B1 (en) 2010-07-26 2013-09-23 Gp-Pharm, S.A. CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.
US8900631B2 (en) 2011-04-28 2014-12-02 Health Science Funding, LLC Dosage form to increase prasterone bioavailability
CN103169712B (en) * 2011-12-20 2017-10-27 重庆华邦制药有限公司 Improve dutasteride's preparation of bioavilability and preparation method thereof
WO2014002015A1 (en) 2012-06-25 2014-01-03 Ranbaxy Laboratories Limited Pharmaceutical composition comprising dutasteride
ES2555485T1 (en) 2014-05-26 2016-01-04 Galenicum Health S.L. Pharmaceutical compositions containing an active agent
KR101679992B1 (en) * 2015-12-31 2016-11-28 주식회사 유유제약 Pharmaceutical composition comprising dutasteride and propylene glycol monolaurate and preparation method of the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
DE3607651A1 (en) * 1986-03-06 1987-09-10 Schering Ag COMBINATION OF AROMATASE INHIBITORS AND TESTOSTERONE-5 (ALPHA) REDUCTASE INHIBITORS
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss

Also Published As

Publication number Publication date
KR20010014080A (en) 2001-02-26
WO1999008666A3 (en) 1999-04-15
CN1263461A (en) 2000-08-16
JP2002511101A (en) 2002-04-09
TR199903209T2 (en) 2000-05-22
CA2295016A1 (en) 1999-02-25
CO4960657A1 (en) 2000-09-25
PE105699A1 (en) 1999-11-25
AR016629A1 (en) 2001-07-25
AU9343098A (en) 1999-03-08
BR9810458A (en) 2000-09-05
WO1999008666A2 (en) 1999-02-25
ZA987392B (en) 2000-02-17
GB9717428D0 (en) 1997-10-22
EP1007010A2 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
ID22891A (en) PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALANOL-DECONGESTANT COMBINATIONS
NO962606D0 (en) Pharmaceutical composition
DZ2516A1 (en) Aerosol pharmaceutical composition.
ID24654A (en) OMEPRAZOLA PHARMACEUTICAL FORMULATION
FI955311A (en) Pharmaceutical composition base
NO980546D0 (en) Pharmaceutical agents
FR2751540B1 (en) ANTITHROMBOTIC PHARMACEUTICAL COMPOSITION
IS5331A (en) New pharmaceutical mix
MA26531A1 (en) PHARMACEUTICAL COMPOSITION
ID29294A (en) PHARMACEUTICAL COMPOSITION
BR9507768A (en) Pharmaceutical composition
LV11727A (en) Pharmaceutical composition
FI973229A0 (en) New pharmaceutical composition
ID25857A (en) PHARMACEUTICAL COMPOSITION
ID18698A (en) PHARMACEUTICAL COMPOSITION
FI973280A (en) Pharmaceutical composition
ITMI962628A0 (en) PHARMACEUTICAL COMPOSITION
BR9605777A (en) Pharmaceutical composition
ID23531A (en) PHARMACEUTICAL COMPOSITION
BR9605131A (en) Pharmaceutical composition
IT1272935B (en) PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN
SE9402924D0 (en) Novel pharmaceutical composition
BR1100755A (en) pharmaceutical composition
BR1101151A (en) Pharmaceutical compounds and composition
KR960016881A (en) Pharmaceutical composition